Two doses of rituximab before transplant may shield children from Epstein-Barr virus

NCT ID NCT07693881

Recruiting now Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 24, 2026 · Updated 5 times

Summary

This trial tests whether giving two doses of rituximab before a stem cell transplant can prevent Epstein-Barr virus (EBV) from reactivating in children. EBV is a common virus that can cause serious illness in children with weakened immune systems after transplant. The study compares children who receive rituximab plus standard care to those who receive standard care alone, tracking EBV levels and side effects for six months after transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab
What this could lead to: If it works, this approach could reduce serious EBV-related complications in children receiving half-matched stem cell transplants, making the procedure safer.
What could go wrong: This is a relatively small, early-stage trial, and rituximab may cause side effects like infusion reactions or increased risk of other infections. The benefit may not be confirmed in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates